Targeting mitophagy for neurological disorders treatment: advances in drugs and non-drug approaches

被引:4
|
作者
Yang, Xiong [1 ]
Zhang, Yu [1 ]
Luo, Jia-xin [1 ]
Zhu, Tao [1 ]
Ran, Zhao [1 ]
Mu, Ben-Rong [1 ]
Lu, Mei-Hong [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Coll Med Technol, Chongqing Key Lab Sichuan Chongqing Coconstruct Di, Chengdu 611137, Peoples R China
基金
中国国家自然科学基金;
关键词
Mitochondrial dysfunction; Mitophagy; Mitophagy pathways; Neurological diseases; Mitophagy target drug; AMYOTROPHIC-LATERAL-SCLEROSIS; MITOCHONDRIAL DYSFUNCTION; IN-VITRO; URSOLIC ACID; HIPPOCAMPAL NEURON; OXIDATIVE STRESS; MUCUNA-PRURIENS; QUALITY-CONTROL; PROHIBITIN; LIFE-SPAN;
D O I
10.1007/s00210-023-02636-w
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mitochondria serve as a vital energy source for nerve cells. The mitochondrial network also acts as a defense mechanism against external stressors that can threaten the stability of the nervous system. However, excessive accumulation of damaged mitochondria can lead to neuronal death. Mitophagy is an essential pathway in the mitochondrial quality control system and can protect neurons by selectively removing damaged mitochondria. In most neurological disorders, dysfunctional mitochondria are a common feature, and drugs that target mitophagy can improve symptoms. Here, we reviewed the role of mitophagy in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, stroke, and traumatic brain injuries. We also summarized drug and non-drug approaches to promote mitophagy and described their therapeutic role in neurological disorders in order to provide valuable insight into the potential therapeutic agents available for neurological disease treatment. However, most studies on mitophagy regulation are based on preclinical research using cell and animal models, which may not accurately reflect the effects in humans. This poses a challenge to the clinical application of drugs targeting mitophagy. Additionally, these drugs may carry the risk of intolerable side effects and toxicity. Future research should focus on the development of safer and more targeted drugs for mitophagy.
引用
收藏
页码:3503 / 3528
页数:26
相关论文
共 50 条
  • [1] Targeting mitophagy for neurological disorders treatment: advances in drugs and non-drug approaches
    Xiong Yang
    Yu Zhang
    Jia-xin Luo
    Tao Zhu
    Zhao Ran
    Ben-Rong Mu
    Mei-Hong Lu
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 3503 - 3528
  • [2] ADVANCES IN NON-DRUG TREATMENT OF SLEEP DISORDERS
    Zhang, Xiaoming
    Dong, Xuewu
    Yang, Cheng
    Wang, Wensheng
    Fang, Jiayan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 9 - 9
  • [3] NON-DRUG TREATMENT
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1978, 20 (26): : 119 - 120
  • [4] NON-DRUG TREATMENT OF HYPERTENSION
    KAPLAN, NM
    ANNALS OF INTERNAL MEDICINE, 1985, 102 (03) : 359 - 373
  • [5] Non-drug treatment of obesity
    Hauner, H
    HERZ, 2001, 26 (03) : 202 - 208
  • [6] Non-Drug Treatment Today
    Karnitsky, Alexander V.
    INTERNATIONAL JOURNAL OF BIOMEDICINE, 2011, 1 (03) : 163 - 166
  • [7] Non-drug treatment for depression
    Bottai, Thierry
    PRESSE MEDICALE, 2008, 37 (05): : 877 - 882
  • [8] Non-drug treatment methods
    Pfeifer, M
    Dreher, R
    Minne, HW
    AKTUELLE RHEUMATOLOGIE, 2001, 26 (05) : 219 - 226
  • [9] NON-DRUG TREATMENT OF HYPERTENSION
    KAPLAN, NM
    TEXAS MEDICINE, 1982, 78 (10) : 52 - 54
  • [10] Non-drug neurological therapy in an acute stroke unit
    Büttner, T
    Bittger, M
    Brosch, R
    Hyweege, E
    Lehmann, N
    Wenning, R
    NERVENHEILKUNDE, 2000, 19 (07) : 366 - 370